BodyTel Successfully Completes ISO13485 Audit.JACKSONVILLE, Fla. -- BodyTel Scientific Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BDYT), a developer of wireless telemedical devices, announces today that it has, through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. and legal manufacturer of the GlucoTel, BodyTel Europe GmbH, successfully completed its initial ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 13485:2003 Certification Audit through its notified body NSAI NSAI Nashville Songwriters Association International NSAI National Standards Authority of Ireland NSAI Non-Steroidal Anti-Inflamatory - National Standards Authority of Ireland The National Standards Authority of Ireland, or NSAI, is the International Organization for Standardization (ISO) member body for the Republic of Ireland. As Ireland’s official standards body, the NSAI aims to inspire consumer confidence and protect industry . ISO 13485:2003 Certification is recognized as a worldwide quality certification specific to the Medical Device industry. The ISO certification as well as a successfully reviewed Technical File is required for a company to sell any medical device in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community and Canada. In order for the company to receive a European Community European Community: see European Union. European Community (EC) Organization formed in 1967 with the merger of the European Economic Community, European Coal and Steel Community, and European Atomic Energy Community. certificate for its GlucoTel product, the company had to demonstrate during the audit that the design and performance of the GlucoTel meet the requirements of the quality standards and directives. BodyTel's successful audit confirmed that the company's quality system was found to meet the requirements established by the EU and other international authorities. Based on audit results, BodyTel was recommended for certification. Certification is expected before the end of the first quarter. Stefan Schraps, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & President of BodyTel, said, "The ISO Audit was a resounding re·sound v. re·sound·ed, re·sound·ing, re·sounds v.intr. 1. To be filled with sound; reverberate: The schoolyard resounded with the laughter of children. 2. success and we are delighted and proud of what we have achieved. Having a successful ISO audit, along with the pending review of our Technical File, means that we are getting closer to European product launch of the GlucoTel. These are very exciting times for all of us." BodyTel's next steps are to complete international clinical studies with the GlucoTel, apply for a Canadian license and move forward to obtain U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance. BodyTel's first market-ready product identified in the scope of the ISO audit and Technical File is the GlucoTel[TM] blood glucose monitoring blood glucose monitoring Sugar monitoring Lab medicine The periodic testing of serum glucose in Pts known to have DM. See Bedside glucose monitoring, Beta cell implants, Diabetes, Glucometer, Glycosylated hemoglobin, Non-Invasive glucose monitoring. and diabetes management This article is about the management of diabetes mellitus. For more on the disease itself see diabetes mellitus. Diabetes is a chronic disease with no cure as of 2007. It is associated with an impaired glucose cycle, altering metabolism. system. It supports patients and doctors in the treatment of diabetes and its corollary diseases. GlucoTel[TM] electronically measures the blood sugar level and then sends test results using Bluetooth technology to the patient's cell phone. Data is then automatically transmitted to an online database via internet connection and stored long-term. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or caregivers, can access the data via internet for review. About BodyTel BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of 'measured body values' to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel's products - GlucoTel, PressureTel and WeightTel are each at different stages of development and approval processes. BodyTel holds a 50% interest in GlucoTel Scientific Inc. which holds the rights to the GlucoTel[TM] blood glucose blood glucose Diabetology The principal sugar produced by the body from food–especially carbohydrates, but also from proteins and fats; glucose is the body's major source of energy, is transported to cells via the circulation and used by cells in the presence meter technology. Further information can be found at www.bodytel.com. Forward Looking Statements Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur. Forward-looking statements in this news release include: Based on audit results, BodyTel was recommended for certification. Certification is expected before the end of the first quarter, that the ISO Audit was a resounding success, Having a successful ISO audit along with the pending review of our Technical File means that we are getting closer to European product launch of the GlucoTel and that BodyTel's next steps are to complete international clinical studies with the GlucoTel, apply for a Canadian license and move forward to obtain U.S. FDA clearance. It is important to note that the Company's actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company's periodic reports filed with the SEC. These reports are available on our investor relations Investor relations The process by which the corporation communicates with its investors. website at www.bodytel.com and on the SEC's website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion